Advances in radiation oncology · 2026
Impact of Consolidation-to-Tumor Ratio on Prognosis After Radiation therapy for Lung Cancer With a Lesion Diameter of 3 cm or Less.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Nakamura Masaki, Hirata Hidenari, Hiroshima Yuichi, Makita Kenji, Saito Satoshi, Baba Hiromi, Someya Takashi, Mukohara Toru, Zenda Sadamoto
Аннотация
PURPOSE: Accurate risk stratification is essential for optimizing radiation therapy for early stage non-small cell lung cancer (NSCLC). This study evaluated whether the consolidation-to-tumor ratio (CTR) or conventional clinical T stage provides superior prognostic value for patients treated with definitive radiation therapy.
METHODS AND MATERIALS: This study included patients with NSCLC with a lesion diameter ≤3 cm, without lymph node or distant metastases, who underwent definitive radiation therapy alone between 2015 and 2022. Patients were categorized into 3 CTR groups: ground-glass opacity (GGO)-dominant (≤0.5), solid-dominant (>0.5 to <1.0), and pure-solid (1.0). Prognostic performance for progression-free survival was compared between CTR-based and T-stage-based models using the Akaike Information Criterion and Concordance Index.
RESULTS: In total, 265 patients (25 GGO-dominant, 39 solid-dominant, and 201 pure-solid) were analyzed. The median follow-up was 50.2 months. No recurrences or deaths were observed in the GGO-dominant group. The pure-solid group exhibited significantly poorer 3-year outcomes than the containing-GGO group (GGO-dominant + solid-dominant) for overall survival (79.0% vs 96.5%) and progression-free survival (64.5% vs 93.1%), with higher rates of distant metastasis. In multivariate analysis, the CTR-based model demonstrated a lower Akaike Information Criterion (895.6 vs 907.4) and a higher Concordance Index (0.69 vs 0.67) than the T-stage-based model, indicating better goodness-of-fit and predictive ability.
CONCLUSIONS: CTR is a robust prognostic indicator, superior to T-stage, in early stage NSCLC treated with radiation therapy. Incorporating CTR into clinical decision-making may provide more accurate risk stratification than tumor size alone.
METHODS AND MATERIALS: This study included patients with NSCLC with a lesion diameter ≤3 cm, without lymph node or distant metastases, who underwent definitive radiation therapy alone between 2015 and 2022. Patients were categorized into 3 CTR groups: ground-glass opacity (GGO)-dominant (≤0.5), solid-dominant (>0.5 to <1.0), and pure-solid (1.0). Prognostic performance for progression-free survival was compared between CTR-based and T-stage-based models using the Akaike Information Criterion and Concordance Index.
RESULTS: In total, 265 patients (25 GGO-dominant, 39 solid-dominant, and 201 pure-solid) were analyzed. The median follow-up was 50.2 months. No recurrences or deaths were observed in the GGO-dominant group. The pure-solid group exhibited significantly poorer 3-year outcomes than the containing-GGO group (GGO-dominant + solid-dominant) for overall survival (79.0% vs 96.5%) and progression-free survival (64.5% vs 93.1%), with higher rates of distant metastasis. In multivariate analysis, the CTR-based model demonstrated a lower Akaike Information Criterion (895.6 vs 907.4) and a higher Concordance Index (0.69 vs 0.67) than the T-stage-based model, indicating better goodness-of-fit and predictive ability.
CONCLUSIONS: CTR is a robust prognostic indicator, superior to T-stage, in early stage NSCLC treated with radiation therapy. Incorporating CTR into clinical decision-making may provide more accurate risk stratification than tumor size alone.